NEW YORK (GenomeWeb News) – RainDance Technologies today said that it has closed a $16.5 million Series E financing round extension.

New investors GE Healthcare and Northgate Capital participated in the round as did existing investors. The financing, Billerica, Mass.-based RainDance said, will be used to accelerate its commercial expansion and assay development work.

RainDance also is developing a liquid biopsy method that uses "readily accessible fluids" and is minimally invasive and inexpensive, it added.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: rare variants linked to bleeding disorder, comparison of whole-exome and whole-genome sequencing, and more.

George Church tells The Sunday Times that his group has inserted some woolly mammoth genes into elephant cells.

A Scientific Reports editor resigns over a new policy at the journal allowing researchers to pay to fast track the peer review of their manuscripts, and poll.

The National Cancer Institute's Harold Varmus discusses the state of cancer research with the New York Times.